Preparation method of key intermediate of kapasitinib
By using an asymmetric chemical synthesis route to prepare key intermediates for carpacitinib, the high cost and low yield problems of existing bio-enzymatic catalysis methods have been solved, achieving efficient and economical intermediate preparation and ensuring drug quality.
Patent Information
- Application Number
- CN202411114658.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-14
- Publication Date
- 2024-11-29
AI Technical Summary
In the existing methods for synthesizing the key intermediate (S)-p-chloro-β-phenylpropanol of carpacitinib, it is difficult to obtain suitable specific enzymes through bio-enzymatic catalysis, resulting in high costs, low yields, and difficulty in controlling impurities, which affects the quality of the drug.
The key intermediate of carpacetinib was prepared by an asymmetric chemical synthesis route, which involved the condensation of R-tert-butylsulfinamide with p-chlorobenzaldehyde, followed by the Reformatsky reaction with ethyl bromoacetate zinc reagent, and then reduction with sodium borohydride.
The preparation of key intermediates for carpacitinib with high conversion rate and high chiral purity was achieved, with a total yield of over 80% and a purity of 99.5%, reducing costs and improving product quality.
Smart Images

Figure CN119039157A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of pharmaceutical chemical industry, and in particular to a method for preparing a key intermediate of capasitinib. Background Art
[0002] Capasertib (code name: AZD5363) is a potent, highly selective, orally active small molecule kinase inhibitor with similar activity against AKT1, AKT2 and AKT3 subtypes. The AKT signaling pathway is associated with the development of endocrine therapy resistance. The drug was developed by AstraZeneca and was approved by the US FDA in November 2023 for use in combination with fulvestrant to treat adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
[0003] The chemical molecular structure of capasitinib is as follows:
[0004]
[0005] It can be seen that the molecular structure is mainly composed of three fragments that are constructed into the final API molecule through synthesis reactions. Because the synthesis of chiral fragments is more difficult, the chiral fragments are placed at the end for splicing, which is conducive to reducing costs. Figure 5 As shown. Patent WO2015181532 (same family CN106661033A) discloses a route for synthesizing capasitinib, which is as follows:
[0006]
[0007] The key intermediate used in the last step of the above route is (S)-p-chloro-β-phenylalaninol (CAS No. 886061-26-3), and the structural formula of the key intermediate is as follows:
[0008]
[0009] The existing synthesis of the key intermediate (S)-p-chloro-β-phenylalaninol requires the synthesis of the carboxylic acid or ester form of the alcohol, namely:
[0010]
[0011] The molecular structure of the carboxylic acid or ester and its synthesis method are reported in some literatures. For example, the synthesis method reported in the literature Organic Process Research & Development 2011, 15, 1201-1206 is as follows:
[0012]
[0013] The synthesis method in this document is to first synthesize a racemic amino-substituted phenylpropionic acid ester, and then selectively hydrolyze one of the configurations through a specific biological enzyme to achieve the purpose of splitting the chiral isomers. The disadvantage of this method is that specific biological enzymes are difficult to obtain. We screened many biological enzymes but did not find a suitable enzyme; at the same time, since the reaction substrate is a racemate, the splitting yield after enzyme hydrolysis will not exceed 50% in theory, which is not atomically economical and has a high cost; in addition, some unpredictable impurities may be generated during the reaction. These trace impurities will make it difficult to study the quality of the final product and it is difficult to ensure the drug quality of capasitinib.
[0014] The above enzyme-catalyzed method is also described in patent US2006178433A1 (same family EP1621529), and the ester form of the substrate is slightly different. However, the disadvantages of this method are the same as those mentioned above, which is not conducive to the quality research of raw materials and the difficulty in obtaining suitable specific enzyme screening. Therefore, the present invention provides a method for preparing a key intermediate of capasitinib with good application prospects. Summary of the invention
[0015] In view of the deficiencies in the prior art, the present invention aims to provide a method for preparing a key intermediate of capasitinib, which can solve the existing problems.
[0016] In order to achieve the above object, the technical solution of the present invention is as follows:
[0017] The present invention is achieved through the following technical solution: a method for preparing a key intermediate of capasitinib, comprising the following steps:
[0018] Step 1: condense R-tert-butylsulfenamide with p-chlorobenzaldehyde to obtain chiral imine CAP-7;
[0019] Step 2: Using the Reformatsky reaction, chiral imine CAP-7 is subjected to asymmetric addition reaction with ethyl bromoacetate zinc reagent to obtain compound CAP-8;
[0020] Step 3: Compound CAP-8 is de-tert-butylsulfenyl protected with hydrochloric acid to obtain compound CAP-9;
[0021] Step 4: Compound CAP-9 is subjected to ester reduction with sodium borohydride in the presence of iodine to obtain compound CAP-SM2, which is the key intermediate of capasitinib;
[0022]
[0023] Furthermore, the specific operation steps of the step 1 are: adding p-chlorobenzaldehyde, tetrahydrofuran, and R-tert-butylsulfenamide to a three-necked flask, stirring after nitrogen replacement and adding tetraethyl titanate, heating to 40-50° C. for reaction for 5-6 hours, cooling the reaction to below 10° C. and adding water for stirring, separating the upper clear liquid, adding ethyl acetate to the lower layer and letting it stand again, separating the upper clear liquid; combining the two supernatants, concentrating under reduced pressure, adding a small amount of methyl tert-butyl ether, stirring and crystallizing, filtering to obtain a filter cake, and vacuum drying to obtain chiral imine CAP-7.
[0024] Furthermore, the preparation method of the ethyl bromoacetate zinc reagent includes: placing zinc powder in a three-necked flask, adding tetrahydrofuran, heating to 40° C., slowly adding tert-butyl bromoacetate, adding over 50 minutes, and reacting at 40° C. for 1 hour after the addition.
[0025] Furthermore, the specific operation steps of the step 2 are: cooling the ethyl bromoacetate zinc reagent to -20°C, adding a tetrahydrofuran solution of the chiral imine CAP-7 dropwise, controlling the internal temperature below -15°C, and adding the solution over 45 minutes; stirring at -15°C for 5 hours; adding saturated brine dropwise to the reaction, adding ethyl acetate, stirring at room temperature for 20 minutes, filtering to remove insoluble matter, separating the organic phase from the filtrate, washing with saturated brine, drying over anhydrous sodium sulfate, and concentrating to obtain a yellow solid compound CAP-8.
[0026] Furthermore, the specific operation steps of step three are: dissolving compound CAP-8 in ethanol, adding hydrochloric acid, and reacting at 20-25° C. for 3.5 hours; concentrating the reaction solution, adding a saturated sodium bicarbonate solution to neutralize it, adding ethyl acetate to extract, washing the organic phase with saturated brine, drying and concentrating to obtain a brown oily crude product, and obtaining a pure compound CAP-9 after column chromatography.
[0027] Further, the specific operation steps of step 4 are: sodium borohydride is placed in a three-necked flask, tetrahydrofuran is added, iodine is added after cooling in an ice bath, compound CAP-9 is added dropwise, the temperature is raised to 40-50°C after addition, and the reaction is carried out for 2.5 hours, methanol is added dropwise to quench the reaction, and then concentrated, water is added, pH is adjusted to 11-13 with 1N sodium hydroxide aqueous solution, dichloromethane is added, and the aqueous phase is separated after filtration, and the aqueous phase is extracted with dichloromethane, and the organic phase is washed with saturated brine, and a small amount of methyl tert-butyl ether is added after drying and concentration, and stirred and crystallized to obtain compound CAP-SM2, i.e., the key intermediate of capasitinib. Compared with the prior art, the beneficial effects of the present invention include:
[0028] The invention provides a method for preparing a key intermediate of capasitinib, namely a method for preparing a key intermediate of capasitinib (S)-p-chloro-β-phenylalaninol. The preparation method of the invention adopts an asymmetric pure chemical synthesis route, has a simple process, a conversion rate of each step is above 80%, and a high total yield. The chiral purity of the prepared key intermediate of capasitinib also reaches above 99.5%. The preparation method of the invention can obtain good economic benefits. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0030] Figure 1 This is the NMR spectrum of the chiral imine CAP-7 according to the embodiment of the present invention;
[0031] Figure 2 This is the NMR spectrum of the embodiment CAP-8 of the present invention;
[0032] Figure 3 This is the NMR spectrum of the embodiment CAP-SM2 of the present invention;
[0033] Figure 4 This is the chiral purity diagram of the embodiment CAP-SM2 of the present invention;
[0034] Figure 5 It is the NMR spectrum of capasitinib API CAP-0 of the present invention. DETAILED DESCRIPTION
[0035] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention are clearly and completely described. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0036] The present invention provides a method for preparing a key intermediate of capasitinib, comprising the following steps:
[0037] Step 1: condense R-tert-butylsulfenamide with p-chlorobenzaldehyde to obtain chiral imine CAP-7;
[0038] Step 2: Using the Reformatsky reaction, chiral imine CAP-7 is subjected to asymmetric addition reaction with ethyl bromoacetate zinc reagent to obtain compound CAP-8;
[0039] Step 3: Compound CAP-8 is de-tert-butylsulfenyl protected with hydrochloric acid to obtain compound CAP-9;
[0040] Step 4: Compound CAP-9 is subjected to ester reduction with sodium borohydride in the presence of iodine to obtain compound CAP-SM2, i.e., the key intermediate of capasitinib: (S)-p-chloro-β-phenylalaninol. The specific synthetic route is:
[0041]
[0042] The preparation method of the present invention will be specifically disclosed below in conjunction with implementation cases:
[0043] (1) Synthesis of chiral imine CAP-7:
[0044]
[0045] The specific operation method is: add 141g (1mol, 1.0eq) of p-chlorobenzaldehyde, 1000ml of tetrahydrofuran, 130g (1.07mol, 1.07eq) of R-tert-butylsulfenamide to a 3000ml three-necked flask, stir after nitrogen replacement and add 460g (2mol) of tetraethyl titanate, heat to 40-50℃ and react for 5-6 hours, and monitor the reaction to be complete. Cool the reaction to below 10℃ and add 1000ml of water. After stirring, separate the supernatant liquid, add 500ml of ethyl acetate to the lower layer and let it stand again, and separate the supernatant liquid. Combine the two supernatants, concentrate under reduced pressure until there is very little solvent, add a small amount of methyl tert-butyl ether, stir and crystallize, filter, and obtain a filter cake. After vacuum drying, 210g of off-white solid powder chiral imine CAP-7 is obtained. Its nuclear magnetic spectrum is as follows Figure 1 As shown, specifically: 1 H NMR (400 MHz, CDCl 3 ):δ8.55(s,1H),7.81-7.77(m,2H),7.48-7.44(m,2H),1.27(s,9H); purity 99.2%, yield 86.4%. 1 H NMR data describing the chiral imine CAP-7 were obtained at 400 MHz using CDCl 3As a solvent, the characteristics of hydrogen nuclear magnetic resonance. δ8.55 (s, 1H): This signal is located at 8.55ppm and is a singlet, indicating that it corresponds to a hydrogen nucleus without neighboring hydrogen atoms (i.e., it does not experience spin coupling); 7.81-7.77 (m, 2H) and 7.48-7.44 (m, 2H): These signals are in the range of 7.81 to 7.77ppm and 7.48 to 7.44ppm, and appear as multiplets, corresponding to two hydrogen nuclei, respectively. 1.27 (s, 9H): This signal is located at 1.27ppm and is a singlet, corresponding to nine hydrogen nuclei.
[0046] (2) Synthesis of compound CAP-8
[0047]
[0048] The preparation method of ethyl bromoacetate zinc reagent is as follows: zinc powder (19.15 g) is placed in a three-necked flask, tetrahydrofuran (100 mL) is added, the temperature is raised to 40° C., tert-butyl bromoacetate (23 g) is slowly added, and the addition is completed over 50 minutes. After the addition is completed, the mixture is reacted at 40° C. for 1 hour.
[0049] The preparation method of CAP-8 is as follows: the above reaction is cooled to -20°C, and a tetrahydrofuran solution of CAP-7 (20.0gin 40mL) is added dropwise, and the internal temperature is controlled to be below -15°C, and the addition is completed in about 45 minutes. After stirring at -15°C for 5 hours, the reaction raw materials disappear. 15ml of saturated brine is added dropwise to the reaction, and 70mL of ethyl acetate is added. The mixture is stirred at room temperature for 20 minutes, and the insoluble matter is removed by filtration. The organic phase is separated from the filtrate and washed with saturated brine (100mL×2), dried over anhydrous sodium sulfate, and concentrated to obtain a yellow solid compound CAP-8 of 26g; the NMR spectrum of the compound CAP-8 is as follows Figure 2 As shown, 1 H NMR (400MHz,CDCl3)δ:7.34-7.26(m,4H),4.87(d,J=4.2Hz,1H),4.79(td,J=6.4,4.1Hz,1H),4.12(qd,J=7.1,0.9Hz,2H),2.87-2.82(m,2H),1.23(s,9H),1.22(s,3H).Yield 95%, HPLC purity 98%, chiral purity 99.0%.
[0050] (3) Synthesis of compound CAP-9
[0051]
[0052] Feeding: Compound CAP-8 (29.06 g) was dissolved in ethanol (185 mL), and 20 mL of hydrochloric acid was added. After reacting at 20-25°C for 3.5 h, the reaction was monitored and the disappearance of the raw material was detected. The reaction solution was concentrated, and after neutralization by adding a saturated sodium bicarbonate solution, 200 ml of ethyl acetate was added for extraction. The organic phase was washed with saturated brine (50 mL × 3), dried and concentrated to obtain 28.6 g of a brown oily crude product. After column chromatography, 18.8 g of a pure product was obtained, with a purity of 98.0% and a yield of 94%.
[0053] (4) Synthesis of key intermediate: (S)-p-chloro-β-phenylalaninol (CAP-SM2)
[0054]
[0055] Sodium borohydride (3.65 g) was placed in a 250 mL three-necked flask, tetrahydrofuran (90 mL) was added, iodine (6.58 g) was added after cooling in an ice bath, and compound CAP-9 (10.0 g in 10 mL THF) was added dropwise. After the addition, the temperature was raised to 40-50 ° C for reaction for 2.5 hours, and the reaction progress was monitored. When the reaction was complete, 50 mL of methanol was added dropwise to quench the reaction, and then concentrated, 50 mL of water was added, and the pH was adjusted to 11-13 with 1N sodium hydroxide aqueous solution, and 100 mL of dichloromethane was added. There were many solids in the system, and the liquid was separated after filtration. The aqueous phase was extracted with dichloromethane 50 mL × 2, and the organic phase was washed with saturated brine 50 mL × 3. After drying and concentration, a small amount of methyl tert-butyl ether was added and stirred for crystallization to obtain 7.4 g of white solid (S)-p-chloro-β-phenylalaninol; its nuclear magnetic spectrum is as follows Figure 3 As shown, 1 H NMR (400MHz, CDCl3) δ: δ7.34-7.29 (m, 2H), 7.27-7.22 (m, 2H), 4.13 (t, J = 6.5 Hz, 1H), 3.78 (t, J = 5.5 Hz, 2H), 2.46 (s, 3H), 1.86 (td, J = 6.9, 6.2, 5.2 Hz, 2H). Yield 90%, chiral purity 99.9%, chiral purity of CAP-SM2 is as follows Figure 4 shown.
[0056] (5) Synthesis of Capasitinib CAP-0
[0057]
[0058] Referring to the synthesis method in patent CN106661033A (same family WO2015181532), CAP-SM2 prepared by the above method of the present invention can be used as a raw material to successfully obtain capasitinib CAP-0. The NMR spectrum of capasitinib is shown in the attached Figure 5 .
[0059] The invention provides a method for preparing a key intermediate of capasitinib, namely a method for preparing a key intermediate of capasitinib (S)-p-chloro-β-phenylalaninol. The preparation method of the invention adopts an asymmetric pure chemical synthesis route, has a simple process, a conversion rate of each step is above 80%, and a high total yield. The chiral purity of the prepared key intermediate of capasitinib also reaches above 99.5%. The preparation method of the invention can obtain good economic benefits.
[0060] It should be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device. In the absence of further restrictions, the elements defined by the sentence "comprise a ..." do not exclude the existence of other identical elements in the process, method, article or device including the elements.
[0061] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that the technical solutions described in the aforementioned embodiments may still be modified, or some of the technical features may be replaced by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A method for preparing a key intermediate of capasitinib, characterized in that: The following steps are involved: Step 1: condense R-tert-butylsulfenamide with p-chlorobenzaldehyde to obtain chiral imine CAP-7; Step 2: Using the Reformatsky reaction, chiral imine CAP-7 is subjected to asymmetric addition reaction with ethyl bromoacetate zinc reagent to obtain compound CAP-8; Step 3: Compound CAP-8 is de-tert-butylsulfenyl protected with hydrochloric acid to obtain compound CAP-9; Step 4: Compound CAP-9 is subjected to ester reduction with sodium borohydride in the presence of iodine to obtain compound CAP-SM2, which is the key intermediate of capasitinib; 2. The method for preparing a key intermediate of capasitinib according to claim 1, characterized in that: The specific operation steps of the step 1 are as follows: adding p-chlorobenzaldehyde, tetrahydrofuran and R-tert-butylsulfenamide into a three-necked flask, stirring after nitrogen replacement and adding tetraethyl titanate, heating to 40-50° C. for reaction for 5-6 hours, cooling the reaction to below 10° C. and adding water for stirring, separating the upper clear liquid, adding ethyl acetate to the lower layer and letting it stand again, separating the upper clear liquid; combining the two supernatants, concentrating under reduced pressure, adding methyl tert-butyl ether for stirring and crystallization, filtering to obtain a filter cake, and vacuum drying to obtain chiral imine CAP-7.
3. The method for preparing a key intermediate of capasitinib according to claim 1, characterized in that: The preparation method of the ethyl bromoacetate zinc reagent comprises: placing zinc powder in a three-necked flask, adding tetrahydrofuran, heating to 40° C., slowly adding tert-butyl bromoacetate, adding the mixture over 50 minutes, and reacting at 40° C. for 1 hour after the addition.
4. The method for preparing a key intermediate of capasitinib according to claim 1, characterized in that: The specific operation steps of the step 2 are: cooling the ethyl bromoacetate zinc reagent to -20°C, adding a tetrahydrofuran solution of the chiral imine CAP-7 dropwise, controlling the internal temperature below -15°C, and adding the solution over 45 minutes; stirring at -15°C for 5 hours; adding saturated brine dropwise to the reaction, adding ethyl acetate, stirring at room temperature for 20 minutes, filtering to remove insoluble matter, separating the organic phase from the filtrate, washing with saturated brine, drying over anhydrous sodium sulfate, and concentrating to obtain a yellow solid compound CAP-8.
5. The method for preparing a key intermediate of capasitinib according to claim 1, characterized in that: The specific operation steps of step 3 are as follows: dissolving compound CAP-8 in ethanol, adding hydrochloric acid, and reacting at 20-25° C. for 3.5 hours; concentrating the reaction solution, adding a saturated sodium bicarbonate solution for neutralization, and then adding ethyl acetate for extraction. The organic phase is washed with saturated brine, dried and concentrated to obtain a brown oily crude product, and then subjected to column chromatography to obtain a pure compound CAP-9.
6. The method for preparing a key intermediate of capasitinib according to claim 1, characterized in that: The specific operation steps of step 4 are as follows: sodium borohydride is placed in a three-necked flask, tetrahydrofuran is added, iodine is added after cooling in an ice bath, compound CAP-9 is added dropwise, the temperature is raised to 40-50° C. after the addition is complete, the reaction is reacted for 2.5 hours, methanol is added dropwise to quench the reaction, the reaction is concentrated, water is added, the pH is adjusted to 11-13 with a 1N aqueous sodium hydroxide solution, dichloromethane is added, the liquids are separated after filtration, the aqueous phase is extracted with dichloromethane, the organic phase is washed with saturated brine, a small amount of methyl tert-butyl ether is added after drying and concentration, and crystallization is stirred to obtain compound CAP-SM2, i.e., the key intermediate of capasitinib.
